Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/MARINUS PHARMACEUTICALS, INC./ SCHEDULE 13G/A

SEC Filing · SCHEDULE 13G/A

MARINUS PHARMACEUTICALS, INC.

SEC Filing

Filed Mar 6, 2025Accepted Mar 6, 2025, 11:18 AM ESTCIK 1267813Accession 0000895421-25-000305
View company →Permanent SEC source ↗
Share

Company context

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. Marinus’ product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the United States in 2022. For more information, please visit www.marinuspharma.com and follow us on Facebook, LinkedIn and X.

Recent company filings

  1. SCHEDULE 13G/A - filed by Beryl Capital Management LLC regarding MARINUS PHARMACEUTICALS, INC.May 15, 2025
  2. 15-12G filingFeb 21, 2025
  3. SCHEDULE 13G/A - filed by Panacea Innovation Ltd regarding MARINUS PHARMACEUTICALS, INC.Feb 14, 2025
  4. SCHEDULE 13G/A - filed by TANG CAPITAL PARTNERS LP regarding MARINUS PHARMACEUTICALS, INC.Feb 14, 2025
  5. EFFECT filingFeb 13, 2025

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗